



The Inception of the Patent System in the Field of Drug Discovery

Merce Garcia*

Department of Administrative Law, University of Granada, Granada, Spain

DESCRIPTION

The field of drug discovery has undergone a significant transformation since the inception of the patent system in the late 15th century, evolving into a complex landscape influenced by scientific innovation, economic imperatives and the regulatory environment. Patents serve as an essential mechanism for protecting intellectual property, promoting innovation and encouraging investment in Research and Development (R&D). This essay explores the historical background of patents in drug discovery, highlights key figures who have contributed to the current system and considers the positive and negative aspects of patent protection in the field.

Historically, the concept of patents originated with the Venetian Patent Statute of 1474, which granted inventors exclusive rights to their inventions for a limited period of time. This framework laid the foundation for modern patent law, fostering an environment conducive to innovation. The pharmaceutical industry began to flourish in the 19th century, leading to the establishment of important patent laws around the world, such as the United States Patent Act of 1790. The landmark case of *Coe v. Bourn* emphasized the importance of patent rights in encouraging technological progress in industry, including the production of drugs. The development of synthetic organic chemistry in the late 19th and early 20th centuries transformed drug discovery, leading to the creation of many therapeutic agents. Figures such as Paul Ehrlich, known for his work in hematology and the development of the first chemotherapeutic agent, arsphenamine, recognized the importance of protecting innovations through patents. Ehrlich's contributions illustrate how scientific advances are closely linked to patent protection mechanisms that allow inventors to capitalize on their discoveries.

The mid-20th century saw a dramatic increase in pharmaceutical R&D, spurred by the successful development of antibiotics, vaccines and antihypertensive drugs. The passage of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, illustrated how patent law can adapt to balance innovation and public health

needs. The law introduced the concept of patent term extension, recognized the lengthy approval processes faced by new drugs and promoted market competition through abbreviated applications for new generic drugs. There are many criticisms regarding the impact of the patent system on access to and affordability of health care. One major concern is that patents can lead to monopolies, leading to exorbitant drug prices that are often beyond the reach of certain segments of the population. For example, the controversy surrounding the high cost of hepatitis C drugs such as Sovaldi (sofosbuvir) illustrates how patent protection can impede access to essential therapies. Critics argue that the profit motive inherent in the patent system undermines ethical considerations in health care, limiting the availability of life-saving medicines, particularly in low-income countries. The shift from a public interest perspective on drug development to a private enterprise model raises ethical questions. The perception of patents as monopolies has sparked patent reform movements and discussions around alternative models, such as open access frameworks or expanded public funding for R&D. Proponents of these models argue that they can democratize access to drugs, allowing for broader distribution of therapeutic innovations without the high cost burden associated with patented treatments.

In the patent debate is Lawrence Lessig, a prominent advocate of open access and intellectual property policies who has emphasized the need to balance innovation and the public good. His work highlights the importance of access to drugs in an era defined by rapid technological progress. In addition, initiatives from organizations such as Médecins Sans Frontières advocate for equitable access to drugs by challenging patent protection through affordable drug campaigns.

In short, the intersection of patents and drug discovery encapsulates a complex story marked by innovation, ethical dilemmas and economic incentives. The historical development of patents has provided a framework for protecting innovations that have led to important medical advances. However, the challenges posed by patent monopolies highlight the need for balanced approaches that prioritize public health while

Correspondence to: Merce Garcia, Department of Administrative Law, University of Granada, Granada, Spain, E-mail: mercegarcia@90.com

Received: 28-Nov-2024, Manuscript No. IPR-25-28434; **Editor assigned:** 30-Nov-2024, PreQC No. IPR-25-28434 (PQ); **Reviewed:** 14-Dec-2024, QC No. IPR-25-28434; **Revised:** 20-Dec-2024, Manuscript No. IPR-25-28434 (R); **Published:** 28-Dec-2024, DOI: 10.35248/2375-4516.24.12.268

Citation: Garcia M (2024). Impact of copyright protection in the field of tourism in Malaysia. *Intel Prop Rights*. 12:268.

Copyright: © 2024 Garcia M. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

encouraging innovation. As the debate continues, it is essential that stakeholders engage in discussions that promote equitable

access to medicines, ensuring that the fruits of scientific progress benefit the entire global population.